Addex Therapeutics (ADXN), a clinical-stage biopharmaceutical company, announced that it has raised gross proceeds of $2.8 million through the sale of 0.44 million American Depositary Shares (ADS) representing 52.54 million shares under its At-the-Market (ATM) offering agreement with H.C. Wainwright...
Addex Therapeutics (ADXN), a clinical-stage biopharmaceutical company, announced the publication of new preclinical research demonstrating that ADX71743, a selective negative allosteric modulator (NAM) of metabotropic glutamate receptor 7 (mGlu7), significantly influences sleep-wake cycles and stress-related neurochemistry in animal models.
Addex Therapeutics (ADXN), a clinical-stage biopharmaceutical company, on Friday announced first quarter financial results, noting a net loss due to reduced incomes. The company specializes in the development of novel small molecule allosteric modulators for the treatment of neurological disorders. Shares...
Addex Therapeutics (ADXN), a clinical-stage biopharmaceutical company, on Thursday announced the full year financial results for 2025 and provided updates on corporate activities and drug development. Operational Highlights The company highlighted certain pharmaceutical developments, including...
Addex Therapeutics (ADXN), a clinical-stage biopharmaceutical company, on Wednesday reported promising preclinical data for its GABAB positive allosteric modulator (PAM) candidate in treating chronic cough associated with idiopathic pulmonary fibrosis (IPF).
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.